Medicenna Therapeutics Corp.
MDNA.TOTSXHealthcare● Active
$0.44
$-0.02(-3.33%)
Market Cap$29900726
P/E Ratio—
52W High$1.97
52W Low$0.41
Medicenna Therapeutics Corp. (MDNA.TO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
MDNA.TO · earnings · updated Jun 8, 2026
Latest Earnings
Q1 FY2026Report Date: Feb 12, 2026EPS Actual
-$0.05
Est. -$0.05 · +0.0%
Revenue
—
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Feb 12, 2026
After Market Close
🔥 4-Quarter EPS Beat Streak
MDNA.TO reports quarterly as a TSX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | Jun 25, 2026 | -$0.06 | — | — | — | $0.00B | — |
| — Q1 FY2026 | Feb 12, 2026 | -$0.05 | -$0.05 | +0.0% | — | — | — |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.06 | -$0.06 | +2.4% | — | — | — |
| ▲ Q3 FY2025 | Jul 29, 2025 | -$0.06 | $0.02 | +133.3% | — | — | — |
| ▲ Q2 FY2025 | Jun 26, 2025 | -$0.06 | $0.02 | +133.3% | — | $0.00B | — |
| ▼ Q1 FY2025 | Feb 13, 2025 | -$0.06 | -$0.07 | -10.5% | — | $0.00B | — |
| ▲ Q4 FY2024 | Nov 14, 2024 | -$0.06 | -$0.05 | +16.7% | — | $0.00B | — |
| ▲ Q3 FY2024 | Jul 31, 2024 | -$0.06 | -$0.05 | +16.7% | $0.00B | $0.00B | -98.9% |
Q2 FY2026
Jun 25, 2026
EPS Actual
—
EPS Est.
-$0.06
EPS Surpr.
—
Revenue
—
Q1 FY2026
Feb 12, 2026
EPS Actual
-$0.05
EPS Est.
-$0.05
EPS Surpr.
+0.0%
Revenue
—
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.06
EPS Surpr.
+2.4%
Revenue
—
Q3 FY2025
Jul 29, 2025Beat
EPS Actual
$0.02
EPS Est.
-$0.06
EPS Surpr.
+133.3%
Revenue
—
Q2 FY2025
Jun 26, 2025Beat
EPS Actual
$0.02
EPS Est.
-$0.06
EPS Surpr.
+133.3%
Revenue
—
Q1 FY2025
Feb 13, 2025Miss
EPS Actual
-$0.07
EPS Est.
-$0.06
EPS Surpr.
-10.5%
Revenue
—
Q4 FY2024
Nov 14, 2024Beat
EPS Actual
-$0.05
EPS Est.
-$0.06
EPS Surpr.
+16.7%
Revenue
—
Q3 FY2024
Jul 31, 2024Beat
EPS Actual
-$0.05
EPS Est.
-$0.06
EPS Surpr.
+16.7%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Q4 FY2026 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Q3 FY2026 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q2 FY2026 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q1 FY2026 | $-0.07 | $-0.06 | $-0.05 | 3 |
| Q4 FY2025 | $-0.06 | $-0.05 | $-0.04 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Feb 12, 2026 | +0.0% | $0.76 | $0.76 | +0.00% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +2.4% | $1.43 | $1.38 | -3.50% |
| ▲ Q3 FY2025 | Jul 29, 2025 | +133.3% | $0.81 | $0.85 | +4.94% |
| ▲ Q2 FY2025 | Jun 26, 2025 | +133.3% | $0.91 | $0.91 | +0.00% |
| ▼ Q1 FY2025 | Feb 13, 2025 | -10.5% | $1.27 | $1.32 | +3.94% |
| ▲ Q4 FY2024 | Nov 14, 2024 | +16.7% | $1.69 | $1.70 | +0.59% |
| ▲ Q3 FY2024 | Jul 31, 2024 | +16.7% | $2.04 | $2.13 | +4.41% |
| ▼ Q2 FY2024 | Jun 27, 2024 | -300.0% | $2.07 | $1.98 | -4.35% |
Q1 FY2026+0.00%
Report Date
Feb 12, 2026
EPS Beat/Miss
+0.0%
Price Before
$0.76
Price After
$0.76
Q4 FY2025-3.50%
Report Date
Nov 12, 2025
EPS Beat/Miss
+2.4%
Price Before
$1.43
Price After
$1.38
Q3 FY2025+4.94%
Report Date
Jul 29, 2025
EPS Beat/Miss
+133.3%
Price Before
$0.81
Price After
$0.85
Q2 FY2025+0.00%
Report Date
Jun 26, 2025
EPS Beat/Miss
+133.3%
Price Before
$0.91
Price After
$0.91
Q1 FY2025+3.94%
Report Date
Feb 13, 2025
EPS Beat/Miss
-10.5%
Price Before
$1.27
Price After
$1.32
Q4 FY2024+0.59%
Report Date
Nov 14, 2024
EPS Beat/Miss
+16.7%
Price Before
$1.69
Price After
$1.70
Q3 FY2024+4.41%
Report Date
Jul 31, 2024
EPS Beat/Miss
+16.7%
Price Before
$2.04
Price After
$2.13
Q2 FY2024-4.35%
Report Date
Jun 27, 2024
EPS Beat/Miss
-300.0%
Price Before
$2.07
Price After
$1.98
Avg Beat Reaction+1.07%
Avg Miss Reaction-0.20%
Beat Rate6 / 8 quarters
Largest Move+4.94% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: MDNA.TO ends December
Medicenna Therapeutics Corp. (MDNA.TO) most recently reported earnings on February 12, 2026 for Q1 FY2026, posting EPS of $-0.05 (in line with the analyst consensus of $-0.05). MDNA.TO has beaten EPS estimates for 4 consecutive quarters. The next MDNA.TO earnings date is expected around September 1, 2026.
Each quarter, investors track MDNA.TO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. MDNA.TO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
MDNA.TO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
MDNA.TO earnings · 4 questionsMedicenna Therapeutics Corp.'s next earnings report is expected around September 1, 2026. MDNA.TO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; MDNA.TO historically reports after market close (AMC).
MDNA.TO earnings datewhen is MDNA.TO earningsMDNA.TO next earnings datewhen does MDNA.TO report earningsMDNA.TO earnings calendar
▸ Source: FMP · Medicenna Therapeutics Corp. SEC filings · US GAAP · Medicenna Therapeutics Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026